
CLAIMS

1. A compound of general Formula (I):

Formula (I):



Formula (I)

or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein:

R^a is H or methyl;

R^1 is selected from the group consisting of:

carbocyclic or -C_{1-6} alkyl-carbocyclic, wherein the carbocyclic group is cyclohexyl or cyclopentyl;

heterocyclic or -C_{1-6} alkyl-heterocyclic group, wherein the heterocyclic group is piperidine, piperazine, morpholine or pyrrolidine;

aryl or -C_{1-6} alkyl-aryl;

heteroaryl or -C_{1-6} alkyl-heteroaryl, wherein the heteroaryl group is pyridine, thiazole or thiophene;

wherein any of the aforesaid carbocyclic, heterocyclic, aryl or heteroaryl groups may optionally be substituted by one or more groups independently selected from:

halo, OH, NH_2 and, for carbocyclic and heterocyclic groups, =O; or

C_{1-4} alkyl, -O(C_{1-4} alkyl), -NH(C_{1-4} alkyl), -NHC(O)(C_{1-4} alkyl), -S(C_{1-4} alkyl), -SO(C_{1-4} alkyl), -SO_2(C_{1-4} alkyl) or -SO_2NH(C_{1-4} alkyl) any of which may be further substituted with halo or OH; or

R^3, -C_{1-4} alkyl-R^3, OR^3, NHR^3, -NHC_{1-4} alkyl-R^3, -OC_{1-4} alkyl-R^3, SR^3, SOR^3 or SO_2R^3;

wherein R^3 is an aryl, heteroaryl, carbocyclic or heterocyclic group any of which may be substituted with one or more halo, C_{1-4} alkyl, -O(C_{1-4} alkyl), NH_2, -NH(C_{1-4} alkyl), -C(O)(C_{1-4} alkyl), -NHC(O)(C_{1-4} alkyl) groups, any of which alkyl groups may be substituted with halo or OH;

each R^2 is independently halo, OH, NH_2; or

C_{1-4} alkyl, -O(C_{1-4} alkyl), -NH(C_{1-4} alkyl), -C(O)(C_{1-4} alkyl), any of which may be further substituted with halo or OH; or

R^4, -C_{1-4} alkyl-R^4, OR^4, NHR^4, -NHC_{1-4} alkyl-R^4, -OC_{1-4} alkyl-R^4, SR^4, SOR^4 or SO_2R^4;

wherein R^4 is an aryl, heteroaryl, carbocyclic or heterocyclic group any of which may be further substituted with one or more halo, OH, C_{1-4} alkyl, -O(C_{1-4} alkyl), NH_2, -NH(C_{1-4} alkyl), -C(O)(C_{1-4} alkyl), -NHC(O)(C_{1-4} alkyl) groups, any of which alkyl groups may be substituted with halo or OH; and

x is 0-4.

2. A compound as claimed in claim 1, wherein R^a is H.

3. A compound as claimed in claim 1 or claim 2 wherein x is 2.

4. A compound as claimed in any one of claims 1 to 3 wherein R^3 is halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy or C_{1-4} haloalkoxy.

5. A compound as claimed in claim 4, wherein there are two R^3 groups, one of which is halo and the other of which is methoxy or halomethoxy.

6. A compound as claimed in any one of claims 1 to 5 wherein R^1 is C_5 or C_6 carbocyclic, C_5 or C_6 heterocyclic, -C_{1-3} alkyl-phenyl, -C_{1-3} alkyl(C_5 or C_6 heteroaryl), -C_{1-3} alkyl(C_5 or C_6 carbocyclic), -C_{1-3} alkyl(C_5 or C_6 heterocyclic), phenyl or C_5 or C_6 heteroaryl, wherein any of the aforesaid cyclic groups may optionally be substituted as described in claim 1.

7. A compound as claimed in claim 6 wherein R^1 is cyclohexyl, cyclopentyl, -C_{1-3} alkyl(cyclohexyl), -C_{1-3} alkyl(cyclopentyl); or R^1 is piperidine, piperazine, morpholine and pyrrolidine, -C_{1-3} alkyl(piperidine), -C_{1-3} alkyl(piperazine), -C_{1-3} alkyl(morpholine), -C_{1-3} alkyl(pyrrolidine); or R^1 is phenyl or -C_{1-3} alkyl-phenyl; or R^1 is pyridine, thiazole, thiophene, -C_{1-3} alkyl(pyridine), -C_{1-3} alkyl(thiazole) or -C_{1-3} alkyl(thiophene), wherein any of the aforesaid cyclic groups may optionally be substituted as described in claim 1.

8. A compound as claimed in any one of claims 1 to 7 wherein R^1 is a -C_{1-3} alkyl(carbocyclic), -C_{1-3} alkyl(heterocyclic), -C_{1-3} alkyl(aryl) or -C_{1-3} alkyl(heteroaryl) group, and the -C_{1-3} alkyl linker is:

-CH_2-;

$-CH(CH_3)-$;
$-CH_2CH(CH_3)-$;
$-CH(CH_3)CH_2-$; or
$-CH_2CH_2-$.

9. A compound as claimed in any one of claims 1 to 8, wherein R^1 is unsubstituted or is substituted, with one or more groups chosen from:

halo, OH, NH_2 and, for carbocyclic and heterocyclic groups, =O; or

C_{1-4} alkyl, $-O(C_{1-4}$ alkyl), $-NH(C_{1-4}$ alkyl), $-NHC(O)(C_{1-4}$ alkyl), any of which may be further substituted with halo or OH; or

R^3, $-C_{1-4}$ alkyl-R^3, OR^3, NHR^3, $-NHC_{1-4}$ alkyl-R^3, $-OC_{1-4}$ alkyl-R^3;

wherein R^3 is an aryl, heteroaryl, carbocyclic or heterocyclic group any of which may be substituted with one or more halo, OH, NH_2 or C_{1-4} alkyl or $-O(C_{1-4}$ alkyl) groups, either of which alkyl groups may be substituted with halo.

10. A compound as claimed in claim 9, wherein R^1 is unsubstituted or is substituted with one or more groups chosen from NH_2, methyl, ethyl, methoxy, ethoxy, chloro, fluoro, trifluoromethyl, trifluoromethoxy, =O (for carbocyclic and heterocyclic groups), NHC(O)Me, R^3, NHR^3, and $NHCH_2R^3$;

wherein R^3 is an aryl, heteroaryl, carbocyclic or heterocyclic group any of which may be substituted with one or more halo, OH, NH_2 or C_{1-4} alkyl or $-O(C_{1-4}$ alkyl) groups, either of which alkyl groups may be substituted with halo.

11. A compound as claimed in claim 9 or claim 10, wherein R^3 is piperidine, 4-methylpiperidine, piperazine, 4-methylpiperazine, thienyl, for example thien-2-yl, thiazolyl, for example thiazol-2-yl, pyridinyl, for example pyridin-2-yl, pyridine-3-yl or pyridine-4-yl, and phenyl.

12. A compound as claimed in claim 1 selected from:

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)cyclohexanecarboxamide;
2-Cyclohexyl-*N*-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)acetamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)piperidine-4-carboxamide;
4-Amino-*N*-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclohexane-carboxamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-5-oxopyrrolidine-3-carboxamide;


N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(4-methoxyphenyl)-acetamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-phenylacetamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(pyridin-4-yl)acetamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(thiophen-2-yl)acetamide;
(2S)-*N*-(4-(5-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-phenylpropanamide;
(2S)-*N*-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(4-methoxyphenyl)-propanamide;
isomers of *N*-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(pyridin-3-yl)propanamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(6-methoxypyridin-3-yl)acetamide;
isomers of *N*-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(pyridin-4-yl)propanamide;
isomers of (2R)-*N*-(4-(5-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(thiophen-2-yl)propanamide;
2-(2-Chloropyridin-4-yl)-*N*-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)acetamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(4-(4-methylpiperazin-1-yl)phenyl)acetamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-3-(pyridin-4-yl)butanamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-((pyridin-4-yl)methyl)-propanamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-3-(pyridin-3-yl)butanamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-((pyridin-3-yl)methyl)-propanamide;
trans-3-Acetamido-*N*-(4-(4-fluoro-2-methoxyphenyl)-pyridin-2-yl)cyclohexanecarboxamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(4-(4-methylpiperazin-1-yl)phenyl)propanamide;
2-(4-(4-Methylpiperazin-1-yl)benzyl)-*N*-(4-(4-fluoro-2-methoxyphenyl)-pyridin-2-yl)propanamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)butanamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-4-(pyridin-2-ylamino)-*cis*-cyclohexanecarboxamide;
N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)acetamide;
cis-*N*-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-4-(pyridin-4-ylamino)-cyclohexanecarboxamide;
cis-3-Acetamido-*N*-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclo-hexanecarboxamide;
(1R,3S)-3-Acetamido-*N*-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclo-pentanecarboxamide;
cis-*N*-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-4-(thiazol-2-ylamino)-cyclohexanecarboxamide;

cis-*N*-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-4-(phenylamino)-cyclohexanecarboxamide;
(1R,3S)-3-(Benzylamino)-*N*-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclopentanecarboxamide;
cis-4-(Benzylamino)-*N*-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclo-hexanecarboxamide;
(1R,3S)-N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-3-(phenylamino)-cyclopentanecarboxamide;
(1R,3S)-3-Acetamido-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclohexanecarboxamide;
(1S,3R)-3-Acetamido-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclopentanecarboxamide;

or their pharmaceutically acceptable salts, solvates or polymorphs, including all tautomers and stereoisomers.


13. A process for the preparation of a compound as claimed in any one of claims 1 to 12, the process comprising:

a. reacting a compound of formula (II):



(II)


wherein R^a and R^2 and x are as defined for formula (I);
with a compound of formula (III):



(III)


wherein R^1 is as defined in claim 1;
using a HATU coupling method; or

b. reacting a compound of formula (VI)



(VI)

wherein R^2 and x are as defined in claim 1 and X is a leaving group, particularly chlorine; with a compound of formula (VII):



(VII)

wherein R^1 is as defined in claim 1;
using a Buchwald type reaction; or

c. deprotecting a protected compound of formula (I) as defined in claim 1; or

d. conversion of a compound of formula (I) as defined in claim 1 to another compound of formula (I) as defined in claim 1.

14. A compound as claimed in any one of claims 1 to 12 for use in medicine, particularly in the treatment of diseases and conditions mediated by the activity of cyclin dependent kinases, especially CDK9.

15. The use of a compound as claimed in any one of claims 1 to 12 in the preparation of an agent for the treatment of diseases and conditions mediated by the activity of cyclin dependent kinases, especially CDK9.


16. A method for the treatment of diseases and conditions mediated by the activity of cyclin dependent kinases, especially CDK9, the method comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1 to 12.

17. A compound, use or method, as claimed in any one of claims 14 to 16, wherein the disease or condition is pain, inflammatory disease, immunological disease, proliferative disease such as cancer, infectious disease, cardiovascular disease or neurodegenerative disease.

18. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 12 as active ingredient together a pharmaceutically acceptable carrier, excipient and/or diluent.

CLAIMS

1. A compound of Formula (I):



Formula (I)

or a pharmaceutically acceptable salt, polymorph, tautomers or stereoisomers thereof wherein:

R^a is H or methyl;

R^1 is selected from the group consisting of:

carbocyclic or -C_{1-6} alkyl-carbocyclic, wherein the carbocyclic group is cyclohexyl or cyclopentyl;

heterocyclic or -C_{1-6} alkyl-heterocyclic group, wherein the heterocyclic group is piperidine, piperazine, morpholine or pyrrolidine;

aryl or -C_{1-6} alkyl-aryl;

heteroaryl or -C_{1-6} alkyl-heteroaryl, wherein the heteroaryl group is pyridine, thiazole or thiophene;

wherein any of the aforesaid carbocyclic, heterocyclic, aryl or heteroaryl groups may optionally be substituted by one or more groups independently selected from:

halo, OH, NH_2 and, for carbocyclic and heterocyclic groups, =O; or

C_{1-4} alkyl, -O(C_{1-4} alkyl), -NH(C_{1-4} alkyl), -NHC(O)(C_{1-4} alkyl), -S(C_{1-4} alkyl), -SO(C_{1-4} alkyl), -SO_2(C_{1-4} alkyl) or -SO_2NH(C_{1-4} alkyl) any of which may be further substituted with halo or OH; or

R^3, -C_{1-4} alkyl-R^3, OR^3, NHR^3, -NHC_{1-4} alkyl-R^3, -OC_{1-4} alkyl-R^3, SR^3, SOR^3 or SO_2R^3;

wherein R^3 is an aryl, heteroaryl, carbocyclic or heterocyclic group any of which may be substituted with one or more halo, C_{1-4} alkyl, -O(C_{1-4} alkyl), NH_2, -NH(C_{1-4} alkyl), -C(O)(C_{1-4} alkyl), -NHC(O)(C_{1-4} alkyl) groups, any of which alkyl groups may be substituted with halo or OH;

each R^2 is independently halo, OH, NH_2; or

C_{1-4} alkyl, -O(C_{1-4} alkyl), -NH(C_{1-4} alkyl), -C(O)(C_{1-4} alkyl), any of which may be further substituted with halo or OH; or

R^4, -C_{1-4} alkyl-R^4, OR^4, NHR^4, -NHC_{1-4} alkyl-R^4, -OC_{1-4} alkyl-R^4, SR^4, SOR^4 or SO_2R^4;

wherein R^4 is an aryl, heteroaryl, carbocyclic or heterocyclic group any of which may be further substituted with one or more halo, OH, C_{1-4} alkyl, -O(C_{1-4} alkyl), NH_2, -NH(C_{1-4} alkyl), -C(O)(C_{1-4} alkyl), -NHC(O)(C_{1-4} alkyl) groups, any of which alkyl groups may be substituted with halo or OH; and

x is 0-4.

2. A compound as claimed in claim 1, wherein R^a is H.

3. A compound as claimed in claim 1 wherein x is 2.

4. A compound as claimed in claim 1 wherein R^2 is halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy or C_{1-4} haloalkoxy.

5. A compound as claimed in claim 4, wherein there are two R^2 groups, one of which is halo and the other of which is methoxy or halomethoxy.

6. A compound as claimed in claim 1 wherein R^1 is C_5 or C_6 carbocyclic, C_5 or C_6 heterocyclic, -C_{1-3} alkyl-phenyl, -C_{1-3} alkyl(C_5 or C_6 heteroaryl), -C_{1-3} alkyl(C_5 or C_6 carbocyclic), -C_{1-3} alkyl(C_5 or C_6 heterocyclic), phenyl or C_5 or C_6 heteroaryl, wherein any of the aforesaid cyclic groups may optionally be substituted as described in claim 1.

7. A compound as claimed in claim 1 wherein R^1 is cyclohexyl, cyclopentyl, -C_{1-3} alkyl(cyclohexyl), -C_{1-3} alkyl(cyclopentyl); or R^1 is piperidine, piperazine, morpholine and pyrrolidine, -C_{1-3} alkyl(piperidine), -C_{1-3} alkyl(piperazine), -C_{1-3} alkyl(morpholine), -C_{1-3} alkyl(pyrrolidine); or R^1 is phenyl or -C_{1-3} alkyl-phenyl; or R^1 is pyridine, thiazole, thiophene, -C_{1-3} alkyl(pyridine), -C_{1-3} alkyl(thiazole) or -C_{1-3} alkyl(thiophene), wherein any of the aforesaid cyclic groups may optionally be substituted as described in claim 1.

8. A compound as claimed in claim 1 wherein R^1 is a -C_{1-3} alkyl(carbocyclic), -C_{1-3} alkyl(heterocyclic), -C_{1-3} alkyl(aryl) or -C_{1-3} alkyl(heteroaryl) group, and the -C_{1-3} alkyl linker is:

$-CH_2-$;

$-CH(CH_3)-$;

$-CH_2CH(CH_3)-$;

$-CH(CH_3)CH_2-$; or

$-CH_2CH_2-$.

9. A compound as claimed in claim 1, wherein R^1 is unsubstituted or is substituted, with one or more groups chosen from:

halo, OH, NH_2 and, for carbocyclic and heterocyclic groups, =O; or

C_{1-4} alkyl, $-O(C_{1-4}$ alkyl), $-NH(C_{1-4}$ alkyl), $-NHC(O)(C_{1-4}$ alkyl), any of which may be further substituted with halo or OH; or

R^3, $-C_{1-4}$ alkyl-R^3, OR^3, NHR^3, $-NHC_{1-4}$ alkyl-R^3, $-OC_{1-4}$ alkyl-R^3;

wherein R^3 is an aryl, heteroaryl, carbocyclic or heterocyclic group any of which may be substituted with one or more halo, OH, NH_2 or C_{1-4} alkyl or $-O(C_{1-4}$ alkyl) groups, either of which alkyl groups may be substituted with halo.

10. A compound as claimed in claim 9, wherein R^1 is unsubstituted or is substituted with one or more groups chosen from NH_2, methyl, ethyl, methoxy, ethoxy, chloro, fluoro, trifluoromethyl, trifluoromethoxy, =O (for carbocyclic and heterocyclic groups), NHC(O)Me, R^3, NHR^3, and $NHCH_2R^3$;

wherein R^3 is an aryl, heteroaryl, carbocyclic or heterocyclic group any of which may be substituted with one or more halo, OH, NH_2 or C_{1-4} alkyl or $-O(C_{1-4}$ alkyl) groups, either of which alkyl groups may be substituted with halo.

11. A compound as claimed in claim 9, wherein R^3 is piperidine, 4-methylpiperidine, piperazine, 4-methylpiperazine, thienyl, thien-2-yl, thiazolyl, thiazol-2-yl, pyridinyl, pyridin-2-yl, pyridine-3-yl, pyridine-4-yl, and phenyl.

12. A compound as claimed in claim 1 selected from:

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)cyclohexanecarboxamide;

2-Cyclohexyl-*N*-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)acetamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)piperidine-4-carboxamide;

4-Amino-*N*-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclohexane-carboxamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-5-oxopyrrolidine-3-carboxamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(4-methoxyphenyl)-acetamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-phenylacetamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(pyridin-4-yl)acetamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(thiophen-2-yl)acetamide;

(2S)-*N*-(4-(5-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-phenylpropanamide;

(2S)-*N*-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(4-methoxyphenyl)-propanamide;

isomers of *N*-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(pyridin-3-yl)propanamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(6-methoxypyridin-3-yl)acetamide;

isomers of *N*-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(pyridin-4-yl)propanamide;

isomers of (2R)-*N*-(4-(5-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(thiophen-2-yl)propanamide;

2-(2-Chloropyridin-4-yl)-*N*-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)acetamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(4-(4-methylpiperazin-1-yl)phenyl)acetamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-3-(pyridin-4-yl)butanamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-((pyridin-4-yl)methyl)-propanamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-3-(pyridin-3-yl)butanamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-((pyridin-3-yl)methyl)-propanamide;

trans-3-Acetamido-*N*-(4-(4-fluoro-2-methoxyphenyl)-pyridin-2-yl)cyclohexanecarboxamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(4-(4-methylpiperazin-1-yl)phenyl)propanamide;

2-(4-(4-Methylpiperazin-1-yl)benzyl)-*N*-(4-(4-fluoro-2-methoxyphenyl)-pyridin-2-yl)propanamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)butanamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-4-(pyridin-2-ylamino)-*cis*-cyclohexanecarboxamide;

N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-2-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)acetamide;

cis-*N*-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-4-(pyridin-4-ylamino)-cyclohexanecarboxamide;

cis-3-Acetamido-*N*-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclo-hexanecarboxamide;

(1R,3S)-3-Acetamido-*N*-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclo-pentanecarboxamide;

cis-*N*-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-4-(thiazol-2-ylamino)-cyclohexanecarboxamide;

cis-*N*-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-4-(phenylamino)-cyclohexanecarboxamide;

(1R,3S)-3-(Benzylamino)-*N*-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclopentanecarboxamide;

cis-4-(Benzylamino)-*N*-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclo-hexanecarboxamide;

(1R,3S)-N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)-3-(phenylamino)-cyclopentanecarboxamide;

(1R,3S)-3-Acetamido-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclohexanecarboxamide;

(1S,3R)-3-Acetamido-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclopentanecarboxamide;

or pharmaceutically acceptable salts, polymorphs, tautomers or stereoisomers thereof.


13. The compound as claimed in claim 1 which is a *cis*-3-acetamido-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclo-hexanecarboxamide.

14. A pharmaceutical composition comprising a compound as claimed in claim 1 as active ingredient together a pharmaceutically acceptable carrier, excipient and/or diluent.

15. The pharmaceutical composition as claimed in claim 14 wherein the active ingredient is *cis*-3-acetamido-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclo-hexanecarboxamide.

16. A process for the preparation of a compound as claimed in claim 1, the process comprising:


a. reacting a compound of formula (II):



(II)

wherein R^a and R^2 and x are as defined for formula (I);

with a compound of formula (III):




(III)

wherein R^1 is as defined in claim 1;

using a HATU coupling method; or


b. reacting a compound of formula (VI)



(VI)

wherein R^2 and x are as defined in claim 1 and X is a leaving group,

with a compound of formula (VII):



(VII)

wherein R^1 is as defined in claim 1;

using a Buchwald type reaction; or

c. deprotecting a protected compound of formula (I) as defined in claim 1; or

d. conversion of a compound of formula (I) as defined in claim 1 to another compound of formula (I) as defined in claim 1.